ArticlePoultry science2026
A novel Bacillus subtilis strain alleviates necrotic enteritis in chickens by reducing NetB toxin from Clostridium perfringens.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotic strategies that attenuate virulence-associated toxins are increasingly recognized as effective approaches to mitigate disease progression. We screened for wildtype Bacillus strains from healthy chickens with the aim of identifying specific isolates capable of reducing Clostridium perfringens toxin production and necrotic enteritis (NE) lesions in chickens and consequently selected a strain (Bacillus subtilis CG4). The cell-free culture supernatant (CFS) of CG4 did not inhibit the growth of a C. perfringens Type G strain. However, the bacterium significantly reduced the level of NetB toxin (a key toxin for NE development) produced by C. perfringens. B. subtilis CG4 was therefore further characterized in vitro and evaluated in vivo for its ability to reduce NE. In the in vitro studies, CG4 produced nearly 3.0 × 10⁸ spores/mL and exhibited resistance to tetracycline and the penicillin only among tested antibiotics. In addition, the CG4 CFS was sensitive to heat and proteinase K treatments, suggesting the proteinaceous nature of a bioactive component. The proteolytic activity of CG4 CFS possessed a relatively broad substrate spectrum, which effectively digested bovine serum albumin (BSA) and casein. In a C. perfringens infection chicken trial that contained three groups of birds (no treatment, pathogen infection only, and pathogen infection with the treatment of CG4) and used a completely random design, the supplementation of B. subtilis CG4 in feed resulted in a significant reduction in NE lesions (p ≤ 0.05) compared to the birds infected with the pathogen only. The average NE sore of birds from the CG4-treated and C. perfringens-infected only groups were 2.47 and 3.75, respectively, while the untreated group had 0 NE lesions. Additionally, CG4-treated chickens exhibited a noticeable increase in body weight (p ≤ 0.05) at the end of trial, presumably through proteolytic activity in CG4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.